Manufacturer: USV Limited, India
Pharmaceutical name: Metformin
Pack: 100 pills (850 mg)
Glycomet is classified within the biguanides group of medications. It helps reduce elevated blood glucose (hyperglycemia) by enabling your body to utilize the insulin produced by your pancreas more effectively.
Metformin acts as an antihyperglycemic agent that enhances glucose tolerance in individuals with type 2 diabetes, thereby reducing both basal and post-meal plasma glucose levels. Its pharmacological mechanisms differ from those of other types of oral antihyperglycemic agents. Metformin reduces liver glucose production, slows down the intestinal absorption of glucose, and enhances insulin sensitivity by promoting glucose uptake and usage in peripheral tissues.
In contrast to sulfonylureas, Glycomet does not lead to hypoglycemia in either individuals with type 2 diabetes or healthy subjects (unless in specific situations, see PRECAUTIONS) and does not cause hyperinsulinemia. During Glycomet treatment, insulin secretion remains stable while fasting insulin levels and the overall plasma insulin response throughout the day may actually decrease.
Glycomet is prescribed to manage blood glucose levels in individuals with diabetes mellitus. It can be utilized in cases of type 1 diabetes, also known as insulin-dependent diabetes or juvenile-onset diabetes, when insulin therapy alone is insufficient for glucose control; and type 2 diabetes, referred to as non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes. It is particularly beneficial for those who are overweight when dietary measures and exercise fail to adequately reduce high blood sugar levels (hyperglycemia).
Glycomet may be administered alone or in conjunction with other diabetes treatments. Its use in children is not generally recommended, except for those with insulin-resistant diabetes receiving treatment in a hospital setting.